Effects of gliclazide and insulin therapy on thromboxane B2 and 6-keta-PGF1alpha levels in type II diabetic patients

Basit Öğe Kaydı
dc.contributor.authorÖzgen, Ahmet Gökhan
dc.contributor.authorÖzmen, Dilek
dc.contributor.authorHamulu, Füsun
dc.contributor.authorÇetin, Metin
dc.contributor.authorYılmaz, Candeğer
dc.contributor.authorBayındır, Oya
dc.date.accessioned2020-12-01T12:14:20Z
dc.date.available2020-12-01T12:14:20Z
dc.date.issued1998
dc.departmentEge Üniversitesien_US
dc.description.abstractDiabetic patients show hemobiolo-gical abnormalities such as increased platelet adhesiveness, platelet hyperaggregability, decreased platelet half life, hemorheological abnormalities and altered fibrinolysis, perhaps contributing to a procoagulative state. Gliclazide, a novel sulfonylurea in routine clinical use, was thought to have effects on prostanoid release and platelet function. We studied thromboxane A metabolite; serum thomboxane B2 (TXB ] and the prostacyclin metabolite, 6-keto-PGF1 to assess the efficacy of gliclazide on these parameters. Two groups of age and sex matched type Il diabetics were examined in the study. There were 16 subjects in each group (F: M= 10/6). the study period was 12 weeks. Gliclazide was given to the first group and insulin to the second. Following parameters were evaluated to see the effect of good control. HbAIc, cholesterol, triglycéride, HDL cholesterol, LDL cholesterol, serum TXB2,6-keto-PGF] levels were measured before and after 3 months of therapy. There was no significant change in TXB2 (2.24±0.2 to 2.08±0.4 nmol/L) and 6-keto-PGF] (2.53±0.2 to 2.15±0.1 nmol/L,) levels in patients treated with insulin despite the amelioration in the HbAIc levels. Therapy ' with gliclazide was followed by a significant decrease in both serum TXB levels (4.18±0.7 to 2.72±0.4, p=0.039] and 6-keto-PGF (2.97±0.3 to 2.03±0.1, p=0.0047)KTXB /6-keto-PGF] ratio did not change both after insulin (1.09±O.S to 1.06±0.8)and gliclazide (1.31±0.9 to 1.32±0.4) treatment. According to the datas in our study, giiclazide therapy decreased TXB2 levels as well as 6-keto-PGF1a levels so that ratio of TXB.,/6-keto-PGF, did not change, which would 1a 3 mean that gliclazide has neutral effect on diabetic microvascular complications.en_US
dc.identifier.endpage435en_US
dc.identifier.issn1300-0144
dc.identifier.issn1303-6165
dc.identifier.issue4en_US
dc.identifier.startpage431en_US
dc.identifier.urihttps://app.trdizin.gov.tr//makale/TmpNd056Yz0
dc.identifier.urihttps://hdl.handle.net/11454/63830
dc.identifier.volume28en_US
dc.indekslendigikaynakTR-Dizinen_US
dc.language.isoenen_US
dc.relation.ispartofTurkish Journal of Medical Sciencesen_US
dc.relation.publicationcategoryDiğeren_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectCerrahien_US
dc.titleEffects of gliclazide and insulin therapy on thromboxane B2 and 6-keta-PGF1alpha levels in type II diabetic patientsen_US
dc.typeOtheren_US

Dosyalar

Koleksiyon

TR-Dizin İndeksli Yayınlar Koleksiyonu